Summary
- A new divide is emerging between the U.S. and EU regarding the screening of biotech intellectual property originating from China.
- The article discusses the implications of this growing rift on international trade and innovation in the biotech sector.
- Key stakeholders are increasingly concerned about national security and economic competition as they navigate these regulatory challenges.
- This development could reshape global biotech collaborations and influence future policy decisions on intellectual property rights.
Join the discussion ā sign up to comment, upvote, and save articles.